Answers are grounded in this paper and cite their sources.
Observational analysis demonstrates three-year outcomes of mitral valve repair in Medicare beneficiaries with degenerative mitral regurgitation, highlighting real-world safety.
Mitral valve repair (MVr) has become the standard therapy for degenerative mitral regurgitation (DMR), but real-world late mortality, reintervention, and readmission data are lacking. This study estimates MVr outcomes for DMR to 3 years in the Medicare fee-for-service population.
No takes yet. Share an insight, caveat, or question.
Thourani et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: